Personalized Immunotherapy Platform
Solid Tumors (Melanoma, Colorectal Cancer, Breast Cancer)
PreclinicalActive
Key Facts
Indication
Solid Tumors (Melanoma, Colorectal Cancer, Breast Cancer)
Phase
Preclinical
Status
Active
Company
About Odimma Therapeutics
Odimma Therapeutics is an early-stage biotech focused on overcoming tumor heterogeneity in oncology through a novel personalized immunotherapy platform. Its approach combines AI and synthetic DNA to design treatments that induce a cellular immune response against patient-specific tumor markers, with demonstrated anti-tumor effects in preclinical models like melanoma, colorectal, and breast cancer. The company is positioned in the rapidly evolving field of precision immuno-oncology, aiming to address hard-to-treat cancers by translating each patient's unique tumor profile into a bespoke therapeutic.
View full company profile